ESP Equity Partners LLC is a private equity investment company working closely with experienced local management teams to acquire pharmaceutical and medical assets in targeted therapeutic areas.
ESP Equity is led by successful healthcare entrepreneurs with extensive international experience and a track record of sourcing undervalued products and executing deals in the US, Asia and South America.
Investment Strategy
Investment Criteria
Investment Methodology >>view more
EKR Therapeutics is a specialty pharmaceutical company, founded in Nov 2005 focusing on identifying, fostering and targeting the growth of products to serve the needs of the acute-care hospital setting. EKR was acquired by Cornerstone Therapeutics (NASDAQ CRTX) for $ 150 MM in 2012.

ESP Chinapharma is a specialty pharma company focusing on registration, sales and marketing of pharmaceutical products in China market. It currently has six products in registration in China, and is the distributor of Pharmascience, a leading Canadian pharmaceutical company.

ESP Pharma. A specialty pharmaceutical company founded in 2002, voted Top 100 company by Venture Reporter, reached $ 90MM revenue in 2004, and sold to Protein Design Labs (NASDAQ: PDLI) for more than $ 500 million dollars in January 2005. Protein Design Labs, Inc. (PDL) is a leading developer of humanized monoclonal
antibody drugs.
May 14, 2012
Cornerstone Therapeutics to Acquire EKR Therapeutics for $150 million dollars
July 14, 2011
EKR Therapeutics Featured on the Global Learning Series Television Series for Fall and Winter Season
September 28, 2010
New Study Demonstrates Ready-to Use Cardene I.V. More Effective than Labetalol for Immediate Control of Blood Pressure in Emergency Room Patients
February 16, 2010
EKR Therapeutics Receives Two Additional Patents for Ready-to-Use Cardene I.V. Bags, Providing Substantial Intellectual Property Protection Through 2027
November 20, 2009
EKR Therapeutics Named Private Company of the Year By New Jersey Technology Council
September 9, 2009
John E. Bailye, Dendrite Founder, Joins EKR Therapeutics as Executive Chairman; Expansion in Board Signifies Key Growth Milestone
September 3, 2009
EKR Therapeutics to Present at the Thomas Weisel Partners 2009 Annual ealthcare Conference
>>view all news
Home | Contacts | Support | Related Links Copyright ©2010 ESP Equity Partners LLC